Matrix metalloproteinases as new targets in Alzheimer's disease: Opportunities and Challenges
http://api.archives-ouvertes.fr/search/?fq=halId_s:hal-03461436&fl=title_s,en_title_s,docid,label_s,en_label_s,authIdHal_s,halId_s,structId_i,uri_s,keyword_s,en_keyword_s,authLastNameFirstName_s,journalTitle_s,abstract_s,en_abstract_s,producedDate_tdate,producedDateY_i,language_s&sort=publicationDate_s+desc
authors
keywords
- Alzheimer's disease
- Brain
- Nervous System
- MMPs
- MT5-MMP
- Inhibitor
- Development
abstract
Although matrix metalloproteinases (MMPs) are implicated in the regulation of numerous physiological processes, evidences of their pathological roles have also been obtained in the last decades, making MMPs attractive therapeutic targets for several diseases. Recent discoveries of their involvement in central nervous system (CNS) disorders, and in particular in Alzheimer's disease (AD), have paved the way to consider MMP modulators as promising therapeutic strategies. Over the past few decades, diverse approaches have been undertaken in the design of
Aix Marseille Université | All rights reserved - Legal notice